FDA sent a second CRL to Telix, delaying its kidney cancer PET drug. Analysts weigh pricing pressure, and growth opportunities.
Telix Gets Second FDA Rejection For Kidney Cancer Drug
Where Today's News Shapes Tomorrow
February 27, 2026
Headlines
